Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations & Corporate Communications John Leonard - President & Chief Executive Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Mary Kate Davis - Bank of America Dae Gon Ha - Stifel Joseph Thome - TD Cowen Luca Issi - RBC ...

| --- | --- | --- | --- | --- | --- | |--------------------|-------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Intellia | is Leading the | | | | | | | Gene Editing Revolution | | | | | | | | | | | | | Corporate Overview | | | | | | | August 2024 | | | | | | | | | | | | | Intellia Therapeutics' Legal Disclaimer 2 This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.06, delivering a surprise of 21.48%. Over the last four quarters, the compan ...

Exhibit 99.1 E, LELEBELLI III PRESS RELEASE #11010101011111111 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter - Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 - Rapid enrollment continues in the Phase 3 MAGNIT ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks. An entrepreneur and a tech visionary, Wood is considered a star stock picker. She's the founder of ARK Invest, which features around $60 billion worth of assets. Part of the reason for considering the ideas she supports is longevity. Wood has b ...

Alfred Pasieka/Stockbyte via Getty Images It's been very hot so far htis summer. I presume you see a problem with the above sentence. It's mostly fine. Including spaces, it has 38 characters. 36 of them are placed correctly. That's whopping 94.7% accuracy! Still, I'm sure it bothers you just to look at it. Try reading it aloud… exactly as written. How comfortable are you even trying to pronounce the next to last word? An editor would presumably change it to: It's been very hot so far this summer. Phew. That ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...